Loading clinical trials...
Loading clinical trials...
Post-Licensure Database Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Conditions
Interventions
Flublok Quadrivalent influenza vaccine RIV4
Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Locations
1
United States
Kaiser Permanente Northern California
Oakland, California, United States
Start Date
September 17, 2018
Primary Completion Date
February 28, 2022
Completion Date
February 28, 2022
Last Updated
May 24, 2022
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions